Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Multidrug-resistant mutations to antiviral and antibody therapy in an immunocompromised patient infected with SARS-CoV-2.

Med (New York, N.Y.) - 10 Nov 2023

Hirotsu Yosuke, Kobayashi Hiroaki, Kakizaki Yumiko, Saito Akitoshi, Tsutsui Toshiharu, Kawaguchi Makoto, Shimamura Sou, Hata Kouki, Hanawa Syunya, Toyama Jun, Miyashita Yoshihiro, Omata Masao

Abstract excerpt

BACKGROUND: Antiviral and antibody therapies for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are being recommended for high-risk patients, but the potential for the development of multidrug-resistant mutations in immunocompromised patients is unclear. METHODS: To investigate the treatment course in cases of prolonged viral shedding in an immunocompromised patient with SARS-CoV-2 infection, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antiviral Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to COVID-19

Share to COVID-19 Clinical Research Studies

Share to Immunocompromised Host

Share to Mutation

Share to SARS-CoV-2

Share to SARS-CoV-2 and COVID-19 Research

Source

Identifiers

PMID: 37683636
DOI: 10.1016/j.medj.2023.08.001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Multidrug-resistant mutations to antiviral and antibody therapy in an immunocompromised patient infected with SARS-CoV-2.PMID 37683636Read ↗

Clinical experience of treatment of immunocompromised individuals with persistent SARS-CoV-2 infection based on drug resistance mutations determined by genomic analysis: a descriptive study.Semantic proximity Read ↗

SARS-CoV-2 evolution during prolonged infection in immunocompromised patientsSemantic proximity Read ↗

Cumulative SARS-CoV-2 mutations and corresponding changes in immunity in an immunocompromised patient indicate viral evolution within the host.Semantic proximity Read ↗

SARS-CoV-2 evolution and evasion from multiple antibody treatments in a cancer patientSemantic proximity Read ↗

Evolution of Antiviral Drug Resistance in SARS-CoV-2Semantic proximity Read ↗

Clinical and Virological Outcome of Monoclonal Antibody Therapies Across SARS-CoV-2 Variants in 245 Immunocompromised Patients: A Multicenter Prospective Cohort Study.Semantic proximity Read ↗

De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report.Semantic proximity Read ↗

Analysis of SARS-CoV-2 mutations associated with resistance to therapeutic monoclonal antibodies that emerge after treatment.Semantic proximity Read ↗

SARS-CoV-2 Evolution and Immune Escape in Immunocompromised PatientsSemantic proximity Read ↗

Persistent SARS-CoV-2 infection and increasing viral variants in children and young adults with impaired humoral immunitySemantic proximity Read ↗

Monitoring for SARS-CoV-2 drug resistance mutations in broad viral populationsSemantic proximity Read ↗

Emergence of multiple SARS-CoV-2 mutations in an immunocompromised hostSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.